Thymosin-α1 for Recurrent Implantation Failure
Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.
-Women 18-40 years [+5]
Identified/correctable non-immune cause of RPL (chromosomal, anatomic, endocrine... [+4]